ArticleFrontiers in endocrinology2025
Case Report: Lifestyle changes and probiotic supplementation for improving longstanding type 2 diabetes in a male undergoing testosterone replacement therapy.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 52-year-old Caucasian male sought treatment for age-related testosterone decline. Past medical history included diagnosed hypertension and type 2 diabetes mellitus, with suboptimal glycemic control and no current antidiabetic therapy. He qualified for testosterone replacement therapy and agreed to address his metabolic dysfunction through enhanced lifestyle interventions and a targeted 5-strain probiotic as well as other supplements. At 3 months, the patient demonstrated improved glycemic control (hemoglobin A1c decreased from 7.2% to 5.9%) and improvement in newly documented mixed hyperlipidemia. At 6 months, testosterone levels normalized with replacement therapy, and the patient achieved modest weight reduction with favorable body composition changes: 13.2-lb decrease in fat mass, as well as a 6.1% reduction in body fat percentage and a 5.1-lb increase in skeletal muscle mass. This case demonstrates the feasibility and clinical efficacy of combining lifestyle interventions with targeted supplementation in a patient with metabolic syndrome who preferred non-pharmacological management strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.